

Transcript Details

This is a transcript of an educational program. Details about the program and additional media formats for the program are accessible by visiting: <https://reachmd.com/programs/medical-industry-feature/research-in-ibd-a-companys-commitment-to-delivering-scientific-breakthroughs/15754/>

ReachMD

www.reachmd.com
info@reachmd.com
(866) 423-7849

Research in IBD: A Company's Commitment to Delivering Scientific Breakthroughs

ReachMD Announcer:

Welcome to ReachMD.

This medical industry feature, titled "Research in IBD: A Company's Commitment to Delivering Scientific Breakthroughs" is sponsored by Pfizer Medical Affairs.

This program is for U.S. healthcare providers only and is intended to be viewed as it was originally produced by Pfizer. The information provided is for educational purposes only and is not intended to replace discussions between patients and healthcare providers.

Pfizer has FDA approved treatments in IBD.

Voiceover:

In advancing innovative discoveries in medicine, Pfizer is committed to delivering scientific breakthroughs to improve the lives of people living with IBD, by leading in science and research.

As pioneers in the IBD space with scientific exploration into monoclonal antibodies and JAK inhibitors, we continue to leverage our history in drug development as we strive to advance the science behind treatments for IBD with investigations that fuel innovation, such as research on S1P receptor modulation.

Our support of research and education demonstrates our commitment to gastroenterology, including IBD patient care and outcomes.

Since 2019, we have extended over 350 grants globally in gastroenterology and have supported >25 clinical IBD fellowships.

Partnerships are important in meeting our commitment to the GI community and patients with IBD beyond medical therapy.

We support patient-centered healthcare initiatives through collaborations with and medical sponsorships of patient organizations and professional societies.

We stay committed to continuously identify factors and implement initiatives to help improve health equity and healthcare access for patients living with IBD.

Our dedication expands to empowering the IBD community to better understand factors that could impact mental health, prevent or reduce comorbidities, and improve the shared decision-making process.

Explore our transformative journey as we strive to advance the science behind treatments for patients with IBD.

ReachMD Announcer:

This program was sponsored by Pfizer Medical Affairs. If you missed any part of this episode, visit Reachmd.com/IndustryFeature. This is ReachMD. Be part of the knowledge.

References:

1. Pfizer's commitment to inflammation and immunology. Pfizer Medical Affairs.
2. Arora Z, Shen B. Biological therapy for ulcerative colitis. *Gastroenterol Rep*. 2015;3(2):103-109.
<https://pubmed.ncbi.nlm.nih.gov/25344680/>

3. Núñez P, Quera R, Yarur AJ. Safety of Janus kinase inhibitors in inflammatory bowel diseases. *Drugs*. 2023;83(4):299-314. <https://pubmed.ncbi.nlm.nih.gov/36913180/>
4. Working to advance care for people living with ulcerative colitis. Pfizer. Accessed August 3, 2023. https://pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2022/story/working-to-advance-care-for-people-living-with-ulcerative-colitis/
5. Competitive grants program. Pfizer. Accessed May 9, 2023. <https://www.pfizer.com/about/programs-policies/grants/competitive-grants>
6. Leading gastroenterology organizations announce funding to improve vaccine utilization and preventive health maintenance. Crohn's & Colitis Foundation. Published March 8, 2019. Accessed May 9, 2023. <https://www.crohnscolitisfoundation.org/leading-gastroenterology-organizations-announce-funding-to-improve-vaccine-utilization>
7. Crohn's & Colitis Foundation and Pfizer, Inc. issue RFP to reduce health disparities in patients with inflammatory bowel disease. Crohn's & Colitis Foundation. Accessed May 9, 2023. <https://www.crohnscolitisfoundation.org/news/RFP-health-disparities>
8. Pfizer. Data on File. 2023
9. Healthcare resource utilisation, common mental health problems, and infections in people with inflammatory bowel disease. ClinicalTrials.gov identifier: NCT03836612. Accessed May 9, 2023. <https://clinicaltrials.gov/ct2/show/NCT03836612>
10. Improving patient care in inflammatory bowel disease (IBD) through shared decision-making. Pfizer. Accessed July 14, 2023. https://cdn.pfizer.com/pfizercom/rfp_files/Shared_Decision_Making_in_IBD_RFP_09182017.pdf?zLukO_9GzVq4TKZKhx2gehY959.rnIlK
11. Patient and caregiver peer coaching intervention to improve patient care and shared decision-making between patients with inflammatory bowel disease and their health care team. Pfizer. Accessed June 5, 2023. <https://www.pfizer.com/node/469956>

© Pfizer Inc. All Rights Reserved.
October 2023. PP-UNP-USA-2948